Oral Citrate Solution

Manufacturer
Brandywine Pharmaceuticals, LLC
Effective date
2025-07-02
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
legacy-cache
Hydrated at
2026-08-01 20:36:15

Label at a glance#

ProductOral Citrate Solution
Active ingredientCITRIC ACID MONOHYDRATE, TRISODIUM CITRATE DIHYDRATE
Label structure11 sections

Dosage and administration

The dose of Oral Citrate Solution is 10 to 30 mL, diluted with water, after meals and at bedtime. The dose should be titrated to achieve the desired effects.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx Only

DESCRIPTION

DESCRIPTION SECTION

The product is a clear, colorless solution containing Citric Acid USP 640 mg/5 mL, and Hydrous Sodium Citrate USP 490 mg/5 mL. These concentrations yield 1 mEq of sodium, equivalent to 1 mEq of bicarbonate per mL of solution.

ACTION

CLINICAL PHARMACOLOGY SECTION

Oral citrate solution is used as a systemic and urinary alkalinizer. Less than 5% of the citrate is excreted in the urine unchanged, since citrate oxidation is to a great extent complete.

INDICATIONS

INDICATIONS & USAGE SECTION

Oral Citrate Solution is indicated for the treatment of metabolic acidosis. This solution is also useful in conditions where long-term maintenance of alkaline urine is needed (e.g. uric acid and cystine calculi of the urinary tract). Oral Citrate Solution is also effective in treatment for acidosis of certain renal tubular disorders.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Oral Citrate Solution is contraindicated in patients with severe renal impairment, oliguria or azotemia, untreated Addison's disease, adynamia episodica hereditaria, acute dehydration, heat cramp, anuria, severe myocardial damage, and hyperkalemia.

PRECAUTIONS

PRECAUTIONS SECTION

The citrate solution should be used with caution in patients with impaired renal function to avoid hypernatremia or alkalosis in the presence of hypocalcemia. Periodic determinations of serum electrolyte levels (especially bicarbonate levels) should be done in patients with renal disease to avoid cardiac failure, hypertension, peripheral and pulmonary edema, and toxemia of pregnancy. The solution should be diluted with water and preferably taken after meals to avoid saline laxative effects.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Citrate solution is generally well tolerated when given in recommended doses when the patient has normal renal functions. To report suspected adverse reactions, contact Brandywine Pharmaceuticals, LLC at 610-314-7943 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The dose of Oral Citrate Solution is 10 to 30 mL, diluted with water, after meals and at bedtime. The dose should be titrated to achieve the desired effects.

HOW SUPPLIED

HOW SUPPLIED SECTION

Oral Citrate Solution is supplied in a 473 mL bottle (NDC 71321-604-16).

PHARMACIST

SPL UNCLASSIFIED SECTION

Dispense in well-closed containers.

STORAGE AND HANDLING SECTION

Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room Temperature].

SPL UNCLASSIFIED SECTION

Brandywine Pharmaceuticals, LLC
West Chester, PA USA
Revised February 2024

PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LabelLabel

NDC 71321-604-16
473 mL

ORAL CITRATE (SHOHL'S) SOLUTION

CONTAINS: Hydrous Sodium Citrate USP 490 mg/5 mL;
Citric Acid USP 640 mg/5 mL;

grape flavor, purified water, sodium

benzoate, sodium saccharin, sorbitol

USUAL DOSAGE: See package insert.

Dispense in a well-closed container.

Store at 20°-25°C (68°-77°F); excursions permitted
to 15°-30°C (59°-86°F). [See USP Controlled Room
Temperature].

GTIN: 00371321604162

Rx Only

Brandywine Pharmaceuticals, LLC

West Chester, PA USA

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
71321-604-16ML - Milliliter71321-604f50cc9cc-9f51-416f-96b9-d70ee9aa7ac312024-03-12

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
71321-60471321-604-16

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
38f4e62a-91f3-a0a4-e063-6394a90a1be511c1130f-ed64-a303-e063-6394a90ab2832025-07-02Adverse reactionsExact identifier
spl id: 38f4e62a-91f3-a0a4-e063-6394a90a1be5
spl set id: 11c1130f-ed64-a303-e063-6394a90ab283

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.